C-fiber spontaneous discharge evoked by chronic inflammation is suppressed by a long-term infusion of lidocaine yielding nanogram per milliliter plasma levels

Pain

Volumn 137, Issue 1, 2008, Pages 218-228

  Xiao, Wen Hua ^a   Bennett, Gary J ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Allodynia; Hyperalgesia; Inflammatory pain; Lidocaine; Muscle

Indexed keywords

FREUND ADJUVANT; LIDOCAINE; SODIUM CHLORIDE;

A FIBER; ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C FIBER; CHRONIC PAIN; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG INFUSION; DRUG INHIBITION; DRUG MECHANISM; HEAT; HYPERALGESIA; HYPERSENSITIVITY; INCIDENCE; INJECTION; MALE; MUSCLE CELL; MUSCLE INNERVATION; MYOSITIS; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN NERVE; STATISTICAL SIGNIFICANCE;

ANIMALS; CHRONIC DISEASE; HYPERALGESIA; INFLAMMATION; INFUSION PUMPS; LIDOCAINE; MALE; NANOSTRUCTURES; NERVE FIBERS, UNMYELINATED; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; TIME;

EID: 44749088870     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2008.02.018     Document Type: Article

References (49)

1. Abram S.E., and Yaksh T.L. Systemic lidocaine blocks nerve injury-induced hyperalgesia and nociceptor-driven spinal sensitization in the rat. Anesthesiology 80 (1994) 383-391
2. Amir R., Argoff C.E., Bennett G.J., Cummins T.R., Durieux M.E., Gerner P., et al. The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain 7 Suppl. 3 (2006) S1-S29
3. Araujo M.C., Sinnott C.J., and Strichartz G.R. Multiple phases of relief from experimental mechanical allodynia by systemic lidocaine: responses to early and late infusions. Pain 103 (2003) 21-29
4. Argoff C.E., Galer B.S., Jensen M.P., Oleka N., and Gammaitoni A.R. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the neuropathic pain scale. Curr Med Res Opin 20 Suppl. 2 (2004) S21-S28
5. Barbano R.L., Herrmann D.N., Hart-Gouleau S., Pennella-Vaughn J., Lodewick P.A., and Dworkin R.H. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch I diabetic polyneuropathy. Arch Neurol 61 (2004) 914-918
6. Berberich P., Hoheisel U., and Mense S. Effects of a carrageenan-induced myositis on the discharge properties of group III and IV muscle receptors in the cat. J Neurophysiol 59 (1988) 1395-1409
7. Black J.A., Liu S., Tanaka M., Cummins T.R., and Waxman S.G. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain 108 (2004) 237-247
8. Boas R.A., Covino B.G., and Shahnarian A. Analgesic responses to i.v. lignocaine. Br J Anaesth 54 (1982) 501-504
9. Burch F., Codding C., Patel N., and Sheldon E. Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial. Osteoarthritis Cartilage 12 (2004) 253-255
10. Cassuto J., Wallin G., Hogstrom S., Faxen A., and Rimback G. Inhibition of postoperative pain by continuous low-dose intravenous infusion of lidocaine. Anesth Analg 64 (1985) 971-974
11. Chabal C., Russel L.C., and Burchiel K.J. The effect of intravenous lidocaine, tocainde, and mexiletine on spontaneously active fibers originating in rat sciatic neuroma. Pain 38 (1989) 333-338
12. Chaplan S.R., Bach F.W., Shafer S.L., and Yaksh T.L. Prolonged alleviation of tactile allodynia by intravenous lidocaine in neuropathic rats. Anesthesiology 83 (1995) 775-785
13. Davies P.S., and Galer B.S. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 64 (2004) 937-947
14. Devor M., and Govrin-Lippmann R. Axoplasmic transport block reduces ectopic impulse generation in injured peripheral nerves. Pain 16 (1983) 73-85
15. Devor M., Govrin-Lippmann R., and Raber P. Corticosteroids suppress ectopic neural discharge originating in experimental neuromas. Pain 22 (1985) 127-137
16. Devor M., Wall P.D., and Catalan N. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain 48 (1992) 261-268
17. Diehl B., Hoheisel U., and Mense S. The influence of mechanical stimuli and of acetylsalicylic acid on the discharges of slowly conducting afferent units from normal and inflamed muscle in the rat. Exp Brain Res 92 (1993) 431-440
18. Djouhri L., and Lawson S.N. A-beta-fiber nociceptive primary afferent neurons: a review of incidence and properties in relation to other afferent A-fiber neurons in mammals. Brain Res Rev 46 (2004) 131-145
19. Ferrante F.M., Paggioli J., Cherukuri S., and Arthur G.R. The analgesic response to intravenous lidocaine in the treatment of neuropathic pain. Anesth Analg 82 (1996) 91-97
20. Flatters S.J.L., and Bennett G.J. Ethosuximide has anti-allodynic and anti-hyperalgesic effects in rat models of paclitaxel and vincristine-induced painful peripheral neuropathies. Pain 109 (2004) 150-161
21. Galer B.S., Gammaitoni A.R., Oleka N., Jensen M.P., and Argoff C.E. Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain. Curr Med Res Opin 20 Suppl. 2 (2004) S5-S12
22. Galer B.S., Jensen M.P., Ma T., Davies P.S., and Rowbotham M.C. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with the use of the neuropathic pain scale. Clin J Pain 18 (2002) 297-301
23. Galer B.S., Rowbotham M.C., Perander J., and Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 80 (1999) 533-538
24. Gammaitoni A.R., Alvarez N.A., and Galer B.S. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol 43 (2003) 111-117
25. Gammaitoni A.R., Galer B.S., Onawola R., Jensen M.P., and Argoff C.E. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the neuropathic pain scale. Curr Med Res Opin 20 Suppl. 2 (2004) S13-S19
26. Gasser H.S., and Grundfest H. Axon diameters in relation to the spike dimensions and the conduction velocity in mammalian A fibers. Am J Physiol 127 (1939) 393-414
27. Gimbel J., Linn R., Hale M., and Nicholson B. Lidocaine patch treatment in patients with low back pain: results of an open-label, nonrandomized pilot study. Am J Ther 12 (2005) 311-319
28. Greene E. Anatomy of the rat (1963), Hafner, New York p. 60-84
29. Hargreaves K., Dubner R., Brown F., Flores C., and Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32 (1988) 77-88
30. Herrmann D.N., Barbano R.L., Hart-Gouleau S., Pennella-Vaughn J., and Dworkin R.H. An open-label study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy. Pain Med 6 (2005) 379-384
31. Kajander K.C., and Bennett G.J. Onset of painful peripheral neuropathy in rat: a partial and differential deafferentation and spontaneous discharge in Aβ and Aδ primary afferent neurons. J Neurophysiol 68 (1992) 734-744
32. Kastrup J., Petersen P., Dejgard A., Angelo H.R., and Hilsted J. Intravenous lidocaine infusion - a new treatment of chronic painful diabetic neuropathy?. Pain 28 (1987) 69-75
33. Katz N.P., Gammaitoni A.R., Davis M.W., and Dworkin R.H. Lidoderm patch study group. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. Pain Med 3 (2002) 324-332
34. Ma Q.P., and Woolf C.J. Progressive tactile hypersensitivity: an inflammation-induced incremental increase in the excitability of the spinal cord. Pain 67 (1996) 97-106
35. Meier T., Wasner G., Faust M., Kuntzer T., Ochsner F., Hueppe M., Bogousslavsky J., and Baron R. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 106 (2003) 151-158
36. Mense S. Nociception from skeletal muscle in relation to clinical muscle pain. Pain 54 (1993) 241-289
37. Mogil J.S., and Crager S.E. What should we be measuring in behavioral studies of chronic pain in animals?. Pain 112 (2004) 12-15
38. Puig S., and Sorkin L.S. Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activity. Pain 64 (1995) 345-355
39. Rossi S.S., Moore A.C., Hagey L.R., Yaksh T.L., and Chaplan S.R. An improved method for the measurement of lidocaine and its metabolites in rat plasma. Ther Drug Monit 19 (1997) 179-184
40. Rowbotham M.C., Davies P.S., and Fields H.L. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol 37 (1995) 246-253
41. Rowbotham M.C., Reisner-Keller L.A., and Fields H.L. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 41 (1991) 1024-1028
42. Sinnott C.J., Garfield J.M., and Strichartz G.R. Differential efficacy of intravenous lidocaine in alleviating ipsilateral versus contralateral neuropathic pain in the rat. Pain 80 (1999) 521-531
43. Tanelian D.L., and MacIver M.B. Analgesic concentrations of lidocaine suppress tonic A-delta and C-fiber discharges produced by acute injury. Anesthesiology 74 (1991) 934-936
44. Wallace M.S., Dyck J.B., Rossi S.S., and Yaksh T.L. Computer-controlled lidocaine infusion for evaluation of neuropathic pain after peripheral nerve injury. Pain 66 (1996) 69-77
45. Wallace M.S., Ridgeway B.M., Leung A.Y., Gerayli A., and Yaksh T.L. Concentration-effect relationship of intravenous lidocaine on the allodynia of complex regional pain syndrome types I and II. Anesthesiology 92 (2000) 75-83
46. Xiao W., and Bennett G.J. Persistent low-frequency spontaneous discharge in A-fiber and C-fiber primary afferent neurons in an inflammatory pain condition. Anesthesiology 107 (2007) 813-821
47. Xiao W., and Bennett G.J. Chemotherapy-evoked neuropathic pain: spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-l-carnitine. Pain 135 (2008) 262-270
48. Xiao W.H., Yu A.L., and Sorkin L.S. Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody. Pain 69 (1997) 145-151
49. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 (1983) 109-110